TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04867265

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mout-to-mouth ventilation
Description: we will record the visibility of chest rising

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mout-to-mouth ventilation
Description: we will record the visibility of chest rising

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mout-to-mouth ventilation
Description: we will record the visibility of chest rising

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mout-to-mouth ventilation with quantitative analysis
Description: we will record the visibility of chest rising, review the ventilation metrics and evaluate each rescue breath in QCPR Skill Reporter

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mout-to-mouth ventilation with quantitative analysis
Description: we will record the visibility of chest rising, review the ventilation metrics and evaluate each rescue breath in QCPR Skill Reporter
Study: NCT05397665

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AT-007
Description: AT-007, aldose reductase inhibitor

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Liquid oral suspension
Study: NCT05792306

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The novel electrolyzed water spray
Description: The researcher use electrolyzed water to treat the diseased area, two times a day, for 5 days. The trial consists of 5 study visits (day 1-day 5). The reduction in the disease area of discomfort, redness and swelling evaluation and adverse event assessments will be performed at each visit. Safety analysis will be assessed based on the reports of adverse events during the study.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: The saline spray
Description: The researcher use saline to treat the diseased area, two times a day, for 5 days. The trial consists of 5 study visits (day 1-day 5). The reduction in the disease area of discomfort, redness and swelling evaluation and adverse event assessments will be performed at each visit. Safety analysis will be assessed based on the reports of adverse events during the study.
Study: NCT05517798

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alveolar ridge preservation
Description: Alveolar ridge preservation is a method of decreasing bone resorption following tooth extraction and facilitating prosthetically-driven implant placement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alveolar ridge preservation
Description: Alveolar ridge preservation is a method of decreasing bone resorption following tooth extraction and facilitating prosthetically-driven implant placement
Study: NCT05640609

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Capeox regimen combined with Sintilimab and Bevacizumab
Description: Stage Ib：Oxaliplatin +Capecitabine Tablets +Sintilimab +Bevacizumab Stage II：Bevacizumab (the dose determined in phase Ib clinical study)，the dosage of other drugs was the same as before
Study: NCT04683458

Intervention type: DEVICE
Intervention: Drug-coated device
Description: The endovascular (intraluminal) application of a medical-device that was coated with paclitaxel
Study: NCT06179316

Intervention type: PROCEDURE
Intervention: Robot Assisted Radical Prostatectomy
Description: Performing radical prostatectomy operation using robotic equipment while preserving bilateral nerve bundles
Study: NCT05567770

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Body Radiation Therapy
Description: Cohort 1 patients with oligometastatic disease will receive Actinium-J591 and Stereotactic Body Radiation Therapy
Study: NCT04279158

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: experience 1 The negative priming task
Description: The targets are presented to the subject on a computer screen. The subject must make an eye or hand movement toward the target and ignore the distracters.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: experience 1 The negative priming task
Description: The targets are presented to the subject on a computer screen. The subject must make an eye or hand movement toward the target and ignore the distracters.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: experience 1 The negative priming task
Description: The targets are presented to the subject on a computer screen. The subject must make an eye or hand movement toward the target and ignore the distracters.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: experience 1 The negative priming task
Description: The targets are presented to the subject on a computer screen. The subject must make an eye or hand movement toward the target and ignore the distracters.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: experience 2 Stop signal task
Description: The targets are presented to the subject on a computer screen. The subject must make an eye movement towards this target. Sometimes a stop signal will appear and the subject will have to avoid to look at the target
Study: NCT05567770

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Androgen Deprivation Therapy
Description: Cohort 2 patient with Polymetastatic disease will receive Actinium-J591 and Androgen Deprivation therapy (ADT)
Study: NCT04279158

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: experience 2 Stop signal task
Description: The targets are presented to the subject on a computer screen. The subject must make an eye movement towards this target. Sometimes a stop signal will appear and the subject will have to avoid to look at the target
Study: NCT06552182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HUC2-344
Description: per oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HUC2-344
Description: per oral
Study: NCT05931575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasudil hydrochloride
Description: Duration of intervention per patient: 22 days; Application scheme: one dose on day 1, two doses on days 2 - 21, one dose on day 22.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasudil hydrochloride
Description: Duration of intervention per patient: 22 days; Application scheme: one dose on day 1, two doses on days 2 - 21, one dose on day 22.
Study: NCT06552182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HUC2-344-R1, HUC2-344-R2
Description: per oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HUC2-344-R1, HUC2-344-R2
Description: per oral
Study: NCT05931575

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.05 ml Quinine dihydrochloride solution (from Quinina Labesfal) in screw flask supplemented with 30 ml Glucose 40% solution from miniplasco directly before use
Study: NCT05163353

Intervention type: DEVICE
Group type: OTHER
Intervention: Treatment with diluted Radiesse
Description: Injection of Décolleté Wrinkles with diluted Radiesse

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment with diluted Radiesse
Description: Injection of Décolleté Wrinkles with diluted Radiesse
Study: NCT06292429

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complex Training
Description: Week 1-4: Foundation Phase Lower Body Resistance Training Squats (Back Squats or Goblet Squats) Deadlifts Lunges~Paired with:~Box Jumps Depth Jumps~Upper Body Resistance Training Bench Press Overhead Press~Paired with:~Medicine Ball Chest Pass Medicine Ball Overhead Throw Rows (Barbell or Dumbbell)~Week 5-8: Strength and Power Phase Lower Body Resistance Training Power Cleans Front Squats Romanian Deadlifts~Paired with:~Box Jumps with Barbell Depth Jumps with Medicine Ball~Upper Body Resistance Training Push Press Pull-Ups or Lat Pulldowns Bent Over Rows~Paired with:~Plyometric Push-Ups Medicine Ball Slam~Week 9-12: Power and Speed Phase Lower Body Resistance Training Snatch Split Squats Jumping Lunges~Paired with:~Box Jumps with Barbell Depth Jumps with Medicine Ball~Upper Body Resistance Training Speed Bench Press Face Pulls Plyometric Pull-Ups~Paired with:~Medicine Ball Chest Pass Medicine Ball Overhead Throw

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Training
Description: Week 0-4 Session 1 Rotator cuff wall compression Forearm flexor compression Alpha ball tricep scrape Band assisted pushups Session 2 Soft ball thoracic breathing Neck ball arm rotations ITb compressions Middle quard compressions~Week 4-8 Session 1 Kneeling pall of band hold Kneeling pall of partner proturbations Leg lower with mediball neutral Half lying arm speed and swing drill Session 2 Single leg band hold Trunk activated psoas lowers Split clam Bulgarian split iso hold~Week 8-12 Session 1 Point kneel thoracic rotations Side lying single arm thoracic abduction Banded side lying clams Side lying abduction from glute Session 2 Low back mobility Kneeling pall off band hold Clean and jerks power drill movements Weighted bench press Session 3 Standing band rotations thoracic only Band pull aparts Tennis ball in trap arm flexion ext thumb to floor Bulgarian weighted

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: No intervention given
Study: NCT06286735

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cinnamomum
Description: 60 capsules of 500 mg of powdered cinnamomum bark (Cinnamomum verum; 40% polyphenols). Participants in this group will be instructed to consume two capsules per day, one after lunch and one after dinner for 3 months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 60 capsules with 500 mg of corn starch per month, until the end of the three months of intervention. Participants in this group will be instructed to consume two capsules per day, one after lunch and the other after dinner for 3 months.
Study: NCT05241756

Intervention type: DEVICE
Intervention: FLACS using FEMTO LDV-Z8
Description: Performance of femtosecond laser-assisted capsulotomy in the anterior capsule.
Study: NCT06092411

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy for Depression
Description: Consists of 8 weekly sessions (group-based, 90-min, 4-6 adolescents in each group). The intervention focuses on addressing depression, with the components such as psycho-education on depression, self-monitoring, behavioural activation, and cognitive restructuring (addressing negative and irrational thoughts often associated with depression in adolescents), relaxation techniques, and relapse prevention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioural Therapy for Depression
Description: Consists of 8 weekly sessions (group-based, 90-min, 4-6 adolescents in each group). The intervention focuses on addressing depression, with the components such as psycho-education on depression, self-monitoring, behavioural activation, and cognitive restructuring (addressing negative and irrational thoughts often associated with depression in adolescents), relaxation techniques, and relapse prevention.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bright Light Therapy
Description: Participants will undergo daily morning light therapy by wearing a validated portable light emitting device (i.e., Re-Timers: https://www.re-timer.com/) at home for 30 minutes. Participants will receive bright blue-green light (500 nm, 506 lux).
Study: NCT04279158

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: experience 2 Stop signal task
Description: The targets are presented to the subject on a computer screen. The subject must make an eye movement towards this target. Sometimes a stop signal will appear and the subject will have to avoid to look at the target

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: experience 3 Anti-saccades
Description: The targets are presented to the subject on a computer screen. The subject must make an eye movement toward this target. Sometimes an instruction will ask the subject to look at the opposite of the target

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: experience 3 Anti-saccades
Description: The targets are presented to the subject on a computer screen. The subject must make an eye movement toward this target. Sometimes an instruction will ask the subject to look at the opposite of the target

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: experience 3 Anti-saccades
Description: The targets are presented to the subject on a computer screen. The subject must make an eye movement toward this target. Sometimes an instruction will ask the subject to look at the opposite of the target

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: experience 3 Anti-saccades
Description: The targets are presented to the subject on a computer screen. The subject must make an eye movement toward this target. Sometimes an instruction will ask the subject to look at the opposite of the target
Study: NCT06087978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C RPT193
Description: Radiolabelled RPT193
Study: NCT04519060

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: phototherapy eye shield
Description: Phototherapy eye shields will be applied to the eyes of infants dilated for scheduled eye exam. They will be worn until four (4) hours after the last dose of dilating eye drops.
Study: NCT04315636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surfactant nebulisation
Description: 200 mg/kg body weight nebulised surfactant (Poractant alfa, Chiesi Farmaceutici SpA, Parma, Italy) via a customised vibrating membrane nebuliser (eFlow neonatal nebuliser system, PARI Pharma, Starnberg).
Study: NCT05943197

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: dental prosthetics, biofilm response and oral microbiota
Description: microbiota, biofilm, oral mucosa

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: dental prosthetics, biofilm response and oral microbiota
Description: microbiota, biofilm, oral mucosa

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: dental prosthetics, biofilm response and oral microbiota
Description: microbiota, biofilm, oral mucosa

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: dental prosthetics, biofilm response and oral microbiota
Description: microbiota, biofilm, oral mucosa
Study: NCT05105815

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPM001
Description: IPM001 will be used against tumor cells
Study: NCT01970124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPS-0373, High dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPS-0373, Low dose
Study: NCT06214039

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure in virtual reality and text based cognitive behavioral therapy (CBT) for public speaking anxiety
Description: A 3-hour one session exposure therapy for public speaking anxiety

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure in virtual reality and text based cognitive behavioral therapy (CBT) for public speaking anxiety
Description: A 3-hour one session exposure therapy for public speaking anxiety
Study: NCT06187519

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Uric Acid and Metabolite Monitor System (UR+AIMS) skin patch
Description: The intervention tested is the system (patch and mobile device/phone for reporting) that provides patients with better knowledge (test results) about the impact of their daily dietary choices on their uric acid levels.
Study: NCT04806334

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI imaging of the pelvis/bladder
Description: The pelvic MRI will be multiparametric (mp)-4D MRI incorporating high resolution diffusion weighted imaging (HR-DWI).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: genomic analysis of tumor
Description: Single cell RNA sequencing of transurethral resection of bladder tumor (TURBT)
Study: NCT05994664

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heartmath Intervention
Description: The participants will all complete baseline surveys and paperwork including signed consent, psychometric surveys, demographic survey, and a brief, open-ended questionnaire about their feelings about living with VEDS. During the initial visit for the intervention group the same assessment will be included, however, they will also receive 10-15 of instruction on a basic Heartmath technique. Group participants will be asked to complete 5-10 minutes of HeartMath techniques 2x daily. Participants from both groups will have weekly virtual sessions that include the 3-step Protocol HRV assessment. However, each week the intervention group will receive an addition 10-15 minutes of training and advancement on HeartMath techniques as well as continued written and video reinforcement.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: The participants will all complete baseline surveys and paperwork including signed consent, psychometric surveys, demographic survey, and a brief, open-ended questionnaire about their feelings about living with VEDS. The initial visit will include an HRV assessment using the HeartMath sensor via the 3-step Protocol developed by the HeartMath Institute. Participants from both groups will have weekly virtual sessions that include the 3-step Protocol HRV assessment. After the CG has completed 8 weeks, they will then have access to materials related to the techniques that were taught to the HMI group to allow for therapeutic equality.
Study: NCT04844086

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RPM CD19-mbIL15-CAR-T cells
Description: Single dose of RPM CD19-mbIL15-CAR-T cells will be infused, and a standard 3+3 design will be applied.~Drug: Fludarabine~Fludarabine is used for lymphodepletion.~Drug: Cyclophosphamide~Cyclophosphamide is used for lymphodepletion
Study: NCT05823155

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Detailed penicillin allergy evaluation
Description: The intervention group will undergo a detailed penicillin allergy evaluation performed by an Infectious Diseases specialist. Components of penicillin allergy evaluation include verification of allergy history (drug involved including dose and route of administration, exact manifestation of labelled allergy and timing of occurrence after use of alleged culprit, history of skin tests or in vitro testing for diagnosis of allergy, subsequent rechallenge of the same or similar antibiotics), followed by skin test (prick test and intradermal test) and oral provocation test as appropriate.
Study: NCT05030662

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking stick exercise
Description: 1. Education of walking stick exercise by research nurses twice before discharge (on the day before surgery and before discharge)~2. The video clip of walking stick exercise is available to the patients.~3. The research nurses encourage our patients to keep rehabilitation by phone calls once a week after discharge.
Study: NCT04631536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin + L-arginine + Folic acid + Nicorandil + Nebivolol
Description: active Comparator: Endothelial dysfunction protocol + Standard of Care (dexamethasone, anticoagulation, vitamin c, zinc). Treatment to be continued until 14 days or discharge/death whichever occurs first. It includes: Nebivolol 5 mg PO daily, Sigmart 10 mg PO twice daily, Atorvastatin 40 mg PO daily, Folic Acid 5 mg PO daily, L-arginine 1000 mg PO 3 times daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo + Standard of Care (dexamethasone, anticoagulation, vitamin c, zinc)
Study: NCT01970137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPS-0373, High dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPS-0373, Low dose
Study: NCT05022303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Larazotide Acetate
Description: AT1001 10 μg/kg/dose up to 500 μg/dose (rounded to the nearest 50 μg) will be administered orally four times a day (QID) to the standard of care for MIS-C.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered orally four times a day (QID) to the standard of care for MIS-C.
Study: NCT06329921

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PTT protocol
Description: Patients will be monitored using the nurse-managed PTT protocol.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: anti-Xa protocol
Description: Patients will be monitored using the pharmacy-managed anti-Xa protocol.
Study: NCT04944186

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Structured Pressure Injury Patient Education (mySPIPE)
Description: It consists of PI education topics which include four main topics; 1) Pressure Injury: Why Me, which will be covering the basic information that patient need to know about PI; 2) Look After Your Skin, in this topics, patient will be thought about how skin checking was done and why it need to be done; 3) Preventing pressure injury, in this topic, patient will be emphasized on the suitable repositioning for them and the benefit of support surfaces and preventive wound dressing; 4) Help your PI heal, in this topic patient will be guided on what are condition that help PI healing and dietary needs to support wound healing

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Patient Education
Description: No fixed content/ duration of patient education. Basically, patient repositioning emphasized verbally after wound dressing completed.
Study: NCT04930627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: dosis depending on body weight: \<20 kg 5 mg 1x/day; 20-40 kg 2 x 5 mg; \>40 kg 2 x 10 mg
Study: NCT06172205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous FOLFOX7 plus Camrelizumab and apatinib
Description: Leucovorin 200mg/m2 administered IV on Days 1 of a 21 day cycle Oxaliplatin 85 mg/m2 IV on Days 1 of a 21 day cycle Fluorouracil 5-FU continuous infusion: 400mg/m2 on D1 and then 2400mg/m2 for 46h of each 21 day cycle.~Camrelizumab 200mg infusion on D1 for every 21 days Apatinib 250mg，po，qd for every 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HAIC-FOLFOX plus Camrelizumab and apatinib
Description: 2-h infusion of oxaliplatin at 85 mg/m2 ,a 2-3-h administration of leucovorin at 400 mg/m2 , and a 46-h delivery of fluorouracil at 2500 mg/m2.~camrelizumab (200 mg intravenously, commencing in 7 days after the first HAIC cycle and repeated every 21 days) and apatinib (250 mg daily, taken orally, beginning in 7 days after the initial HAIC cycle) Camrelizumab 200mg infusion on D1 for every 21 days Apatinib 250mg，po，qd for every 21 days
Study: NCT05006508

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle tool
Description: Regular use of the digital Lifestyle tool